NCT00500266

Study Evaluating Safety of 13-Valent Pneumococcal Conjugate Vaccine in Healthy Elderly Subjects

A Phase 3, Open-Label, Single-Arm Trial Evaluating the Safety, Tolerability, & Reactogenicity of a 13vPnC Vaccine in Ambulatory Elderly Adults Aged 68 Years & Older Who Received 1 or More Doses of 23vPS Vaccine at Least 3 Years Before Study Enrollment

• Status: Completed
• Phase: Phase 3
• Study type: Interventional
• Enrollment: 1,053 (actual)
• Sponsor: Pfizer · Industry
• Sex: All
• Age: 68 Years
• Healthy volunteers: Accepted

Summary

To evaluate the safety of 13-valent pneumococcal conjugate vaccine (13vPnC) in elderly subjects who were vaccinated with one or more doses of 23-valent pneumococcal polysaccharide vaccine (23vPS) at least 3 years before study enrollment.

Conditions

• Pneumococcal Infections

Interventions

Type	Name	Description
BIOLOGICAL	13-valent Pneumococcal Conjugate Vaccine (13vPnC)

Timeline

• Start date: 2008-05-01
• Primary completion: 2009-04-01
• Completion: 2009-05-01
• First posted: 2007-07-11
• Last updated: 2011-09-16
• Results posted: 2011-09-16

Locations

59 sites across 3 countries: United States, Germany, Sweden